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Abstract
Background: Diabetic nephropathy is one of the most serious complications in patients with diabetes. At present,
there are no satisfactory treatments available for diabetic nephropathy. Stem cells are currently the main candidates
for the development of new treatments for diabetic nephropathy, as they may exert their therapeutic effects mainly
through paracrine mechanisms. Exosomes derived from stem cells have been reported to play an important role in
kidney injury. In this article, we try to investigate whether exosomes retrieved from urine stem cells could itself
prevent diabetic nephropathy at an early stage in vivo and in vitro.
Methods: Exosomes from conditioned medium of urine-derived stem cells (USCs-Exo) were isolated using
ultrafiltration-combined purification methods. USCs-Exo were then verified by morphology, size, and specific
biomarkers using transmission electron microscopy, tunable resistive pulse sensing analysis, and western blotting.
After establishment of the streptozotocin-induced Sprague–Dawley rat model, the effects of USCs-Exo on kidney
injury and angiogenesis were observed via weekly tail intravenous injection of USCs-Exo or control until 12 weeks.
In vitro, podocytes cultured in high-glucose medium were treated with USCs-Exo to test the protective effect of
USCs-Exo on podocytic apoptosis. Meanwhile, the potential factors in promoting vascular regeneration in USCs-Exo
and urine-derived stem cell conditioned medium were investigated by enzyme-linked immunosorbent assay.
Results: Urine-derived stem cells were cultured and were verified by positive markers for CD29, CD73, CD90 and
CD44 antigens, and negative markers for CD34, CD45 and HLA-DR. USCs-Exo were approximately 50–100 nm
spherical vesicles, and the specific markers included CD9, CD63 and CD81. Intravenous injections of USCs-Exo could
potentially reduce the urine volume and urinary microalbumin excretion, prevent podocyte and tubular epithelial
cell apoptosis, suppress the caspase-3 overexpression and increase glomerular endothelial cell proliferation in
diabetic rats. In addition, USCs-Exo could reduce podocytic apoptosis induced by high glucose in vitro. USCs-Exo
contained the potential factors, including growth factor, transforming growth factor-β1, angiogenin and bone
morphogenetic protein-7, which may be related with vascular regeneration and cell survival.
Conclusion: USCs-Exo may have the potential to prevent kidney injury from diabetes by inhibiting podocyte
apoptosis and promoting vascular regeneration and cell survival.
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Background
Diabetic nephropathy (DN) is one of the most common
and serious complications of capillaries in patients with
diabetes. At the time of writing, DN affects 20–40 % of
patients with diabetes mellitus [1, 2]. There is no satis-
factory method or target for the treatment of DN.
Hyperglycemia-induced damage to the glomerular
podocyte—the terminally differentiated epithelial cells
attached to the glomerular basement membrane—is
thought to be a critical early event in DN. High glucose
contributes to reduced podocyte numbers, induces
apoptosis of cultured podocytes, causes albuminuria and
accelerates foot process effacement [3]. Interventions
that prevent podocyte damage or loss have been demon-
strated to have potential for the treatment of DN [4].
DN is also characterized by abnormal angiogenesis
driven by several factors, including hyperglycemia and
ischemia [5, 6]. Vascular endothelial cells and podocytes
act as the barrier to macromolecular flow into the urin-
ary filtrate. The endothelial–podocytes participate in the
glomerular filtration barrier, whereby the actions of one
type of cell may profoundly influence the function of the
other [7]. Interventions that prevent podocyte damage
or loss and promote angiogenesis are potential treat-
ments for DN. Bone marrow-derived stem cells as well
as mesenchymal stem cells (MSCs) were envisioned for
the development of this type of treatment. It has been
suggested that the transient presence of MSCs within
the injured kidneys may provide a paracrine support for
the healing process, including the secretion of cytokines,
chemokines and growth factors [8, 9].
Stem cell-derived exosomes have been described as a
new mechanism of cell-to-cell communication which
have emerged as an important paracrine factor [9]. Exo-
somes are secreted nanovesicles (30–100 nm diameter)
formed through the inward budding of multivesicular
bodies that exosomes traffic and transfect proteins,
mRNAs and micro-RNAs into target cells could induce
tubular differentiation of human vascular endothelial
cells (HUVECs) in vitro [10, 11]. Furthermore, new data
shows that conditioned media from adipocyte-derived
MSCs have the potential to protect podocytes from
high-glucose-induced damage, which may be related to
the epidermal growth factor secreted by exosomes [12, 13].
Human urine-derived stem cells (USCs) can be con-
veniently obtained through noninvasive methods. Such
methods are thought to be a new portal of access into
stem cells [14]. Single clones of USCs can expand to
yield a large population, and they have the capacity for
multipotent differentiation [15].
In the present study, we investigated the therapeutic
effects of exosomes from USCs (USCs-Exo) in a strepto-
zotocin (STZ)-induced rat model. We found that intra-
venous injections of USCs-Exo could reduce the urine
volume and urinary microalbumin excretion. Under fur-
ther analysis, we found that the apoptosis of podocytes
and tubular epithelial cells was prevented, the overex-
pression of caspase-3 was suppressed, and the prolifera-
tion of glomerular endothelial cells was increased, which
indicated that inhibiting podocyte apoptosis or promot-
ing vascular regeneration may be one means of prevent-
ing kidney complications arising from diabetes. In vitro,
USCs-Exo could reduce podocytic apoptosis and con-
tained the potential factors which may be related to vas-
cular regeneration and cell survival. To our knowledge,
this is the first study to suggest that USCs-Exo could
prevent kidney complications from diabetes, which indi-
cates that USCs-Exo can be a novel regulator in DN
therapy.
Methods
Ethics, consent and permissions
This study was performed in accordance with the princi-
ples of the Helsinki Declaration and was approved by the
Ethical Review Board of Shanghai Jiao Tong University
Affiliated Sixth People’s Hospital. Human urine samples
were collected from six healthy men with a median age of
25 years. Written informed consent was obtained from all
study participants. Experiments using Sprague–Dawley
(SD) rats were approved by the Animal Care and Use
Committee of Shanghai Jiao Tong University Affiliated
Sixth People’s Hospital.
Isolation and culture of USCs
USCs were isolated and identified as previously de-
scribed [16, 17]. Briefly, penicillin and streptomycin were
added to the fresh urine samples (200 ml) at the recom-
mended concentrations to minimize contamination.
After the urine sample was centrifuged at 400 × g for 10
minutes at room temperature, the supernatant was
discarded and the sediment was washed twice with
phosphate-buffered saline (PBS). The resulting sediment
was re-suspended in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 2 % (vol/vol) fetal bovine
serum (FBS; Gibco, USA), 10 ng/ml of human epidermal
growth factor (hEGF), 2 ng/ml of platelet-derived growth
factor (PDGF), 1 ng/ml of transforming growth factor
(TGF)-β, 2 ng/ml of basic fibroblast growth factor
(bFGF), 0.5 μM hydrocortisone, 25 μg/ml of insulin,
20 μg/ml of transferrin, 549 ng/ml of epinephrine,
50 ng/ml of triiodothyronine (T3), L-glu and antibiotics.
The cell suspension was plated into gelatin-coated 24-well
plates and incubated at 37 °C in a humidified atmosphere
with 5 % CO2. The medium was changed after 7 days,
and the nonadherent cells were removed by thor-
oughly washing with PBS. Colonies that were derived
from single cells were marked. The culture medium
was refreshed twice per week. The cells were passaged
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using 0.25 % trypsin when they reached approximately
80 % confluence.
Flow cytometry analysis of USCs
Passage 4 USCs were incubated with 3 % bovine serum
albumin for 30 minutes to block nonspecific antigens.
The cells were then incubated with the following mono-
clonal antibodies (Becton Dickinson, USA): CD29-PE,
CD73-PE, CD90-PE, CD44-FITC, CD45-FITC, CD34-
APC and HLA-DR-PE. Nonspecific fluorescence was de-
termined by incubation of similar cell aliquots with iso-
type-matched monoclonal antibodies (BD Biosciences).
The cells were washed to remove unbound antibodies.
Surface antigens were analyzed using a Guava easyCyte™
(Millipore, Billerica, MA, USA).
Isolation and purification of USCs-Exo
USCs-Exo were prepared and purified as previously de-
scribed. Kosaka et al. [18] and Montecalvo et al. [19]
80–90 % confluent USCs were washed with PBS and cul-
tured for an additional 48 hours at 37 °C and 5 % CO2
in the special USC medium with exosome-free FBS. The
conditioned medium was collected and centrifuged at
2500 × g for 20 minutes at 4 °C. After the centrifugation,
the supernatant was filtered using a 0.22-μm filter
sterilize SteritopTM (Millipore, USA) to remove the
remaining cells and cellular debris. Then, the super-
natant was transferred to an Ultra-clear tube (Millipore,
USA) and centrifuged at 100,000 × g for 70 minutes
at 4 °C to deposit USCs-Exo, and then the supernatant
was decanted. The USCs-Exo pellet was resuspended
in 200ul of PBS. In order to further purification, the
liquid containing USCs-Exo was laid on top of 30 %
sucrose/D2O cushion in a sterile Ultra-Clear™ tube
(Beckman Coulter, Kraemer Boulevard Brea, CA,
USA) and centrifuged at 100,000 × g for 70 minutes
at 4 °C (Beckman Coulter, Sorvall, Avanti J-26XP,
fixed angle rotor). USCs-Exo was recovered using an
18-G needle and finally dissolved in 200 μl of PBS.
USCs-Exo were stored at −80 °C or used for other
downstream experiments. USCs-Exo protein contents
were determined using the BCA assay following the
instructions (Thermo Fisher, USA). The absorbance
was read at 562 nm using a Microplate Reader (Bio-Rad
Laboratories, USA).
Transmission electron microscopy of USCs-Exo
The USCs-Exo fraction was assessed by transmission
electron microscopy (TEM). The exosome pellets were
fixed in 3 % (w/v) glutaraldehyde and 2 % paraformalde-
hyde in cacodylate buffer, and then loaded to copper
grids coated with Formvar. After washing, the grids were
contrasted in 2 % uranyl acetate, dried, and then exam-
ined by TEM (Morgagni 268D, Philips, Holland).
Tunable resistive pulse sensing analysis of USCs-Exo
The size distribution and concentration of USCs-Exo
were measured by tunable resistive pulse sensing (TRPS)
analysis. TRPS measurements were performed using a
qNano platform with an NP100-rated nanopore (Izon
Science, UK). The membrane was stretched at 43.0 mm.
CPC100 particles (Izon Science) were used to calibrate
the size and concentration following manufacturer’s in-
structions. Samples were diluted 1000-fold with 0.22-μm
filtered PBS and measured for 3 minutes. Data process-
ing and analysis were carried out on the Izon Control
Suite software v2.2 (Izon Science).
Western blotting analysis of USCs-Exo
The identity of USCs-Exo had been confirmed by the
presence of the specific surface proteins CD9, CD63 and
CD81 [20]. Briefly, 5× protein-loading buffer was added
directly to the USCs-Exo sample and heated at 95 °C for
5 minutes. Next, USCs-Exo protein was loaded and re-
solved in 12 % sodium dodecyl sulfate/polyacrylamide
gel electrophoresis. The protein sample was run at 120
V for 45 minutes and transferred onto polyvinylidene
difluoride membranes (Millipore, USA) for 1.5 hours at
100 mA. The presence of CD9, CD63 and CD81 was
tested by exposing the membranes to primary rabbit
polyclonal anti-CD9 (1:1000), anti-CD63 (1:1000) and
anti-CD81 (1:1000) (Abcam, UK). The membranes were
washed three times in 1× Tris-HCl buffered saline
Tween (TBS and 0.1 % Tween 20; TBST) for 5 minutes,
and incubated for 1 hour in TBST containing horserad-
ish peroxidase-conjugated goat anti-rabbit secondary
antibody (Abcam). Proteins were detected using en-
hanced chemiluminescence (Thermo Fisher, USA) and
imaged using an Image Quant LAS 4000 mini bio-
molecular imager (Bio-Rad, USA).
Diabetes rat model and injection of USCs-Exo
Diabetes was induced by a single injection of STZ
(Sigma, USA) 65 mg/kg administered to male SD rats
(200–250 g). Control rats received citrate buffer. Fifty
SD rats were used, and ten were used in preliminary ex-
periments. 10 SD rats did not reach the criteria of dia-
betes and were excluded. Ten were used as a control
group and 20 were randomly grouped as the diabetes
group and the diabetes treated with USCs-Exo group.
Blood glucose was measured from tail vein blood. Dia-
betes was defined as a random blood glucose reading
≥16.7 mmol/l for three consecutive days after 72 hours
of STZ injection. SD rats who met the criteria for dia-
betes were randomized to be treated or untreated. The
rats of the USCs-Exo treatment diabetic group were
injected weekly with Exo (100 μg of Exo dissolved in
PBS to final volume of 200 μl) via the tail vein [21].
Other diabetic rats (n = 10) were given the same volume
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of control medium dissolved in PBS to 200 μl. The ran-
dom blood glucose and body weight of each rat was
measured every week. Twenty-four-hour urine speci-
mens were collected from all rats every 4 weeks, and
centrifuged at 3000 rpm for 10 minutes at 4 °C. The
supernatant was measured for albumin concentration.
Results of urinary albumin were normalized to urinary
creatinine levels and expressed as urinary albumin-to-
creatinine ratio (UACR). Blood samples were collected
from all rats every 4 weeks. The supernatant of blood
samples from the tail vein was reserved after centrifuga-
tion at 3000 rpm for 10 minutes at 4 °C in order to
measure biochemical parameters, including blood glu-
cose, blood urea nitrogen, serum creatinine, and finally
tested by an automatic biochemistry analyzer (Hitachi
Model 7600, Japan). Twelve weeks after the induction of
diabetes, rats were sacrificed under chloral hydrate
anesthesia, and kidneys were obtained. The left kidneys
were divided into two parts. One part was washed by
PBS and fixed with 10 % buffered formalin for paraffin
production, for the use of TUNEL analysis, periodic
acid-schiff (PAS) staining and immunofluorescence. The
other part was separated into the cortex and medulla, in
which cortex was immediately placed in liquid nitrogen
for tissue protein extraction for Western blotting. The
right kidneys were dealt with in the same way, and
conserved for later use. Glomerular injury was evalu-
ated by mesangial expansion in sections stained with
hematoxylin and eosin under light microscopy (200X).
The mesangial area was counted as mesangial expansion,
which was determined in 20 consecutive glomeruli from
each rat. All slides were observed independently by two
blinded investigators. Relative mesangial expansion was
described as the fold change from the normal control
group.
TUNEL assay
After deparaffinization (using xylene and ethanol dilu-
tion) and rehydration the sections were stained for
TUNEL Kit (11684817910, Rocha Applied Science,
Switzerland) as described in the Kit instructions. Briefly,
each slide was deparaffinized and rehydrated, and
treated with proteinase K (20 mg/l) for 15 minutes. The
endogenous peroxidase was inhibited with 3 % hydrogen
peroxide for 5 minutes, and then incubated with the
TUNEL reaction mixture containing terminal deoxynu-
cleotidyl transferase (TdT) and digoxigenin-11-dUTP for
1 hour. The TdT reaction was carried out in a humidi-
fied chamber at 37 °C, and then 3,3-diaminobenzidine
chromogen was applied. Hematoxylin was used as coun-
terstaining. For the negative control, TdT was omitted
from the reaction mixture. Apoptotic cell number was
quantitatively analyzed by counting the TUNEL-
positive cells selected randomly from 10 fields, at 40×
magnification. Results were presented as the number
of TUNEL-positive cells per 103 cells.
Analysis of caspase-3 protein expression
Renal cortical protein was separated by dodecyl sulfate/
polyacrylamide gel electrophoresis and transferred to a
polyvinylidene difluoride membrane. The membranes
were then blocked by incubation in TBST containing
5 % bovine serum albumin and incubated overnight
at 4 °C with the primary antibody, caspase-3 (ab32351;
Abcam, USA). Relative protein expression was described
as the fold change from the normal control group.
Immunofluorescence staining of CD31
The expression of CD31 known as platelet-endothelial
cell adhesion molecule-1 was detected by immunofluor-
escence staining in each group. Briefly, the paraffin sec-
tions were placed in an oven at 60 °C for 1 hour and
then rehydrated in a graded ethanol series (100 %, 95 %,
90 %, 85 %, and 70 %). Citrate buffer was used for heat-
induced antigen retrieval. Then goat serum was used as
a blocking solution before the primary antibody was
applied. The sections were incubated overnight in 4 °C
with rabbit anti-rat CD31 antibody at a 1:150 dilution
(Abcam, USA), and mouse anti-rat Ki-67 (a marker of
proliferation) antibody at a 1:100 dilution (Abcam,
USA).The secondary antibody, goat anti-rabbit antibody
conjugated to Alexa Fluor 594 (BA1032, China) and
goat anti-mouse antibody conjugated to Alexa Fluor
488 (Life, USA) were applied at 1:200 dilutions for 1
hour. Then immunofluorescence photomicrographs
were obtained at 400× magnifications using a fluores-
cence microscope (Leica, Solms, Germany), and the
intensity of the CD31-positive signal was quantified
with Image pro plus 6.0 image analysis software (Media
Cybernetics, USA) to represent glomerular endothelial cell
proliferation.
PAS staining
The kidneys were stained with PAS. The sections were
then examined by light microscopy. Glomerular injury
was evaluated by mesangial expansion in sections
stained with PAS. Summarily, the mesangial area was
counted as mesangial expansion, which was determined
in 20 consecutive glomeruli from each rat. Relative
mesangial expansion was described as the fold change
from the normal control group.
Podocyte culture with high glucose in vitro
Conditionally immortalized human podocytes were ob-
tained from Dr. Moin Saleem, Bristol, UK, and later do-
nated to us by John Cijiang. Podocytes were cultured as
described previously [22]. Briefly, podocyte recovery was
at 33 °C, used an RPMI 1640 medium containing 10 %
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FBS and 1 × ITS culture proliferated. Then, cells were in-
oculated into different six-well plates and were cultured
for at least 7 days as a mature podocyte at 37 °C so they
could be used for the tests [23]. The cells were cultured
synchronously in medium containing 0.1 % FBS and 5.5
mM D-glucose RPMI-1640 medium for 24 hours before
the test. Then they were divided into six groups accord-
ing to treatment: normal glucose (5.5 mM), mannitol
control (5.5 mM D-glucose + 24.5 mM mannitol), high
glucose (30 mM), and treatment groups with USCs-Exo
(5 μg/ml, 10 μg/ml and 50 μg/ml). Each group was
subjected to its own designated treatment regimen for
72 hours.
Flow cytometry analysis detection of podocytic apoptosis
According to the operation instructions of Annexin V-
FITC/PI Apoptosis Detection Kit (Dojindo, Kumamoto,
Japan), podocytes (5 × 105/ml) were collected and sus-
pended with 200 μl of binding buffer, and then 10 μl of
Annexin-v-FITC and 5 μl of PI were added for a 15 mi-
nute light cycle avoiding incubation at room temperature.
Lastly, the cells were resuspended in 250 μl of binding
buffer and analyzed using the guava easyCyteTM system
(Millipore, Billerica, MA, USA). The experiment had three
replicates.
Cytokines in USCs-Exo detected by enzyme-linked
immunosorbent assay
The concentrations of vascular endothelial growth factor
(VEGF), TGF-β1, angiogenin and bone morphogenetic
protein (BMP)-7 were determined in USCs-Exo and
USC conditioned medium (USC-CM) according to the
manufacturer’s instructions. Primitive USC medium was
taken as control. Optical density (OD) was measured at
450 nm. The concentration of candidate factors in the
samples was calculated according to standard curves.
Three independent samples were placed in three repeti-
tive holes.
Statistical analysis
The data are listed as means ± standard deviation. Statis-
tical analyses were carried out using GraphPad Prism
5.0. Two-way analysis of variance (ANOVA) or one-way
ANOVA was used to compare differences in outcome
variables between different groups. Subgroup analysis
was performed by S-N-K test. A result was considered
statistically significant at P < 0.05.
Results
USC phenotype
Cell colonies were observed in the USC-cultured plates
approximately 7 to 10 days after initial plating. USCs
were confirmed using light microscopy to verify a
fibroblast-like morphology (Fig. 1a, left panel). The
fibroblast-like cells had a robust proliferation capability
and reached 80–90 % confluence after 16 days (Fig. 1a,
middle panel). After several passages, USCs retained the
elongated morphology (Fig. 1a, right panel). As the cri-
terion to identify stem cells, cell surface markers must
be analyzed. We used flow cytometry analysis (FCM) to
detect the surface antigen expression. The results dem-
onstrated that the USCs were positive for CD29, CD73,
CD90 and CD44 antigen and negative for CD34, CD45
and HLA-DR (Fig. 1b). When cultured in osteogenic,
adipogenic, or chondrogenic media, the USCs could dif-
ferentiate into osteoblasts, adipocytes and chondrocytes
as previously reported by the authors [16, 17]. Thus, the
characterization of USCs meets the criteria for defining
multipotent MSCs.
Characterization of USCs-Exo
To investigate the roles of USCs-Exo in diabetic rats,
USCs-Exo were extracted and identified. The morph-
ology of USCs-Exo was observed under TEM, and their
size was measured by Nano Sight analysis. The results of
TEM showed that USCs-Exo were spherical vesicles of
about 100 nm (Fig. 1c). TRPS analysis showed that the
size of USCs-Exo were approximately 50–100 nm
(Fig. 1d), which was in accord with TEM. The results of
Western blotting showed that exosomes markers, in-
cluding CD9, CD63 and CD81, were expressed in USCs-
Exo (Fig. 1e).
Intravenous injection of USCs-Exo could reduce the urine
volume and urinary microalbumin excretion of diabetic
rats
We established the rat model of DN induced by in-
traperitoneal injection of STZ to test the hypothesis
that USCs-Exo has some beneficial effects on the kid-
ney in diabetic rats. The results showed that polyuria
was evidently improved in the diabetes treated with
USCs-Exo group compared with the diabetes only
group (Fig. 2, left panel). To evaluate the level of
microalbuminuria in different groups, urinary albumin
concentration was expressed as UACR. Compared
with the normal group, the rats in the diabetes model
group showed a marked elevation of UACR (Fig. 2,
right panel). USCs-Exo treatment significantly sup-
pressed UACR of diabetes rats at every time point
(Fig. 2, right panel). Blood glucose was significantly
increased in STZ-induced diabetic rats when com-
pared with normal control rats. However, no differ-
ences in blood glucose, serum creatinine or blood
urea nitrogen were observed between USCs-Exo
treated and untreated diabetic rats (Additional file 1:
Table S1). These results suggest that USCs-Exo may
play an important role in preventing renal function
decline in type 1 diabetic rats.
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Intravenous injection of USCs-Exo could prevent cells
apoptosis and suppressed caspase-3 overexpression in
diabetic rats
We assessed podocyte and tubular epithelial cell apop-
tosis in diabetic rats by TUNEL staining and further
tested caspase-3, an apoptosis-related protein. There was
a significant decrease in apoptotic cells in kidney sec-
tions from diabetes treatment with USCs-Exo (P < 0.05)
(Fig. 3a). TUNEL assay showed some TUNEL-positive
cells in the glomerular and tubule region in diabetic rats
(Fig. 3ab). However, the apoptosis-positive cells in the
normal control group (Fig. 3aa) and diabetes treatment
with USCs-Exo rats (Fig. 3ac) were very few. Following
on from this, Western blotting was used to measure
caspase-3, an apoptosis-related protein. We observed
that the relative activated caspase-3 protein (activated-
cas3/β-actin) and intact caspase-3 (intact-cas3/β-actin)
protein levels in diabetic rats were higher than those in
the normal group (P < 0.05) (Fig. 3b). Then, compared
with the diabetic group, USCs-Exo downregulated
caspase-3 protein overexpression (P < 0.05) (Fig. 3b).
Intravenous injection of USCs-Exo could promote
glomerular endothelial cell proliferation in the early stage
of diabetic kidney impairment
As we know, the glomerular filtration barrier is com-
posed of endothelial cells, basement membrane and
podocytes. The loss of glomerular capillaries plays an
important role in albuminuria production and renal
function decline. The results of immunofluorescence
Fig. 1 Characteristics of USCs and USCs-Exo. a) The morphology and growth of USCs. Scale bar = 200 μm. b) USCs were characterized by flow
cytometry using the surface markers CD29, CD90, CD73, CD44, CD34, CD45 and HLA-DR. White solid peaks represent the isotype controls and the
grey solid peak represents the marker indicated. c) Morphology of USCs-Exo under a transmission electron microscopy. d) TRPS measurement
showed that the size range of USCs-Exo concentrated at 50–100 nm, and the measured mean concentration (particles/ml) of USCs-Exo was
5.2E + 009. e) Western blotting analysis of exosome-specific CD9, CD63 and CD81 proteins in USCs and USCs-Exo. USC Urine-derived stem
cell, USCs-Exo Exosome from urine-derived stem cells
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Fig. 2 Intravenous injection of USCs-Exo could reduce the urine volume and urinary microalbumin excretion in type 1 diabetic rats. Changes in
urinary volume and urinary albumin to creatinine ratio (UACR) in different groups were analyzed. Values are shown as the mean ± standard deviation
for the groups normal (n = 10), diabetes (n = 10), and diabetic rats treated with USCs-Exo (n = 10). *P < 0.05, versus normal; #P < 0.05, versus diabetic
rats + USCs-Exo. Cr Creatinine, USCs-Exo Exosome from urine-derived stem cells, W Weeks
Fig. 3 Intravenous injection of USCs-Exo could attenuate the expression of apoptosis-related protein and TUNEL-positive cells. a) Tissue apoptosis
was examined with TUNEL-positive staining; (a) normal, (b) diabetes, (c) diabetes treated with USCs-Exo and (d) semi-quantitative analysis for
apoptotic examination was scored. b) The relative protein levels of activated caspase-3/β-actin and intact caspase-3/β-actin was detected by Western
blotting. *P < 0.05, versus normal; #P < 0.05, versus diabetes + USCs-Exo. USCs-Exo Exosome from urine-derived stem cells
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co-stain with CD31 and Ki-67 showed that endothelial
cells had obvious proliferation. The amount of CD31- and
Ki-67-positive endothelial area was moderately increased
in the diabetes + USCs-Exo group (Fig. 4c), but there were
no obvious Ki-67-positive areas in the normal group
(Fig. 4a) or diabetes group (Fig. 4b).
Intravenous injection of USCs-Exo ameliorated the renal
histopathology
Twelve weeks after the establishment of the diabetes
model, the diabetic rats showed focal mesangial matrix
expansion compared to normal rats (Fig. 5a). Kidney
sections from diabetic rats revealed a remarkable glom-
erular hypertrophy and increased intraglomerular cells
mostly in the mesangial area with mesangial expansion
(Fig. 5b). In diabetic rats with USCs-Exo, however, there
were only modest increases in the mesangial matrix and
intraglomerular cells, with no apparent signs of glom-
erular hypertrophy and mesangial matrix proliferation
(Fig. 5c). The results of quantitative analysis showed that
USCs-Exo treatment significantly ameliorated mesangial
expansion (P < 0.05) (Fig. 5d).
USCs-Exo could reduce podocytic apoptosis induced by
high glucose in vitro
To define the role of USCs-Exo in changes to cell apop-
tosis in rats, we added USCs-Exo to human podocytes
exposed to high glucose for 72 hours in vitro. The num-
ber of apoptotic or necrotic cells was quantified by FCM
analysis after staining with Annexin V and PI (Fig. 6a).
The cytograms show viable cells that did not bind
Annexin V or PI in the D3 quadrant. Cells in the early
stages of apoptosis that bound Annexin V but still had
intact cell membranes and excluded PI are shown in the
D4 quadrant. Cells with advanced stages of apoptosis or
necrosis that were both Annexin V- and PI-positive are
shown in the D2 quadrant. Cells that lost their intact cell
membranes that bound PI and excluded Annexin V are
shown in the D1 quadrant. The results are presented in
the form of a percentage, and showed that the early
podocytic apoptosis rate in the D4 quadrant was sig-
nificantly higher in the high glucose group than in
normal glucose group (26.73 versus 2.36 %), and
USCs-Exo-reduced podocytic apoptosis was induced
by high glucose in a dose-dependent manner (13.5
versus 9.7 versus 5.2 %; P < 0.05) (Fig. 6b).
USCs-Exo may contain the potential factors for promoting
angiogenesis and cell survival
To investigate the potential mechanisms by which
USCs-Exo inhibited podocytic apoptosis, increased
glomerular endothelial cells and promoted glomerular
angiogenesis, we performed enzyme-linked immuno-
sorbent assay (ELISA) to determine whether podocyte
Fig. 4 Double immunofluorescent staining of CD31 (red) and Ki-67
(green). a) normal group, b) diabetes group, and c) diabetes treated
with USCs-Exo group. Representative photomicrographs of the
designated area
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survival factor (BMP-7) and angiogenesis related pro-
teins (VEGF, TGF-β1 and angiogenin) were present in
USCs-Exo [13, 24]. The results demonstrated that VEGF,
TGF-β1, angiogenin and BMP-7 were significantly higher
in USC-CM and USCs-Exo than controls (P < 0.05)
(Fig. 7). In addition, there were no significant differences
between USCs-Exo and USC-CM. Based on these data,
we all but confirmed that USCs secreted exosomes carry-
ing some BMP-7 and high levels of VEGF, TGF-β and
angiogenin to be involved in renal protection in diabetes.
Discussion
In this study, we obtained human-derived stem cells and
tested their multipotent capacity. We successfully ob-
tained USCs-Exo and investigated their role in diabetic
rats. USCs-Exo treatment significantly suppressed UACR
in diabetic rats. Intravenous injection of USCs-Exo could
prevent podocyte apoptosis by suppressing caspase-3
overexpression and increasing glomerular endothelial
cell proliferation in the early stage of diabetes in the test
subjects. USCs-Exo could reduce podocytic apoptosis
induced by high glucose in vitro. USCs-Exo and USC-
CM contained the potential factors (VEGF, TGF-β1,
angiogenin and BMP-7) for promoting vascular regen-
eration and cell survival.
DN is the leading cause of end-stage renal disease and
is defined by pathological changes in the kidney causing
progressive loss of glomerular filtration rate, proteinuria
and tubulointerstitial fibrosis. Treatments currently
available include tight glucose and blood pressure con-
trol and blockade of the renin–angiotensin system,
which can delay, but not prevent, the development of
DN. Consequentially, the need to develop new therapies
to target DN is essential. Several factors have been
shown to influence the progression of DN after the on-
set of albuminuria; TGF-β, angiotensin II, and advanced
glycated proteins have been extensively characterized
[4]. Furthermore, podocytes are highly differentiated
cells that play an important role in the pathogenesis of
DN [25]. Our study was carried out based on these
mechanisms behind DN. Podocytes and endothelial cells
mainly take part in the formation of the filtration barrier.
Glucose at high levels could reduce the number and
density of podocytes, destroy the integrity of the glom-
erular filtration membrane and change its selective
permeability, so as to promote the progression of
Fig. 5 Intravenous injection of USCs-Exo could ameliorate the renal histopathology changes in diabetic rats at 12 weeks. Representative light
microscope appearance of PAS staining in glomeruli. (a) normal, (b) diabetes, and (c) diabetes treated with USCs-Exo. Purple-red represents a
positive region, suggesting mesangial matrix proliferation. (d) Quantitative analysis of mean mesangial area from each group of rats. Magnification
400×. Results are expressed as the means ± standard deviation. *P < 0.05, versus normal; #P < 0.05, versus diabetes. USCs-Exo Exosome from
urine-derived stem cells
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glomerular sclerosis and accelerate the progression of
DN. Meanwhile, the loss and injury of interacting
proteins of podocytes could activate apoptosis and des-
troy the integrity of the slit membrane, which in turn
aggravates proteinuria and accelerates DN progression
[4, 26, 27]. On the other hand, angiogenesis is the for-
mation of new vascular segments originating from exist-
ing vessels, which is characterized by a combination of
sprouting of new vessels from the sides and ends of
pre-existing ones or by longitudinal division of existing
vessels with periendothelial cells. As there is proven
interaction between podocytes and endothelial cells,
angiogenesis might be related to the mechanism of DN.
Angiogenesis requires many interactions that must be
regulated by a wide range of angiogenic inducers, includ-
ing growth factors, chemokines, angiogenic enzymes,
endothelial-specific receptors, and adhesion molecules, as
well as various endogenous angiogenesis inhibitors [6, 28].
Fig. 6 USCs-Exo could reduce apoptosis of human podocyte cells induced by high glucose (HG). a) Representative FCM photograph of PI and
AnnexinV-FITC double stained podocyte apoptosis. b) The bar chart of PI and AnnexinV-FITC double stained podocyte apoptosis. *P < 0.05, HG
group versus normal glucose (NG) group; #P < 0.05, HG group versus HG treated with USCs-Exo group. MA Mannitol
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Stem cell therapies have been studied in several kidney
injury models. Many studies indicated that it is the para-
crine pathway rather than a direct effect responsible for
stem cell damage repair. It is likely that a large complex
rather than a single small molecule (believed to be
microvesicles), or the exosomes, are responsible for the
paracrine pathway [29–31]. Exosomes were first found
to be secreted by sheep reticulocytes approximately 50
years ago. They have since been shown to be secreted by
many cell types, including B cells, dendritic cells, mast
cells, platelets, and so forth. They are also found in
physiological fluids such as normal urine, plasma and
bronchial lavage fluid. They have a diameter of 40–100
nm, with a density in sucrose of 1.13–1.19 g/ml. Most
exosomes have an evolutionarily conserved set of pro-
teins, including tetraspanins (CD81, CD63 and CD9),
Alix and Tsg101, yet they also have unique tissue/cell
type-specific proteins that reflect their cellular source.
The large diversity in exosome-secreting cell types and
the presence of exosomes in different physiological fluids
indicate that secretion of exosomes is a common cellular
function. They are believed to be important for intercel-
lular communications [32]. Exosomes may act as im-
portant paracrine/endocrine mediated factors, which can
transfer specific protein, mRNA and microRNA. Unlike
cells, exosomes do not elicit acute immune rejection
and, being nonviable and much smaller, they pose less
safety risks such as the formation of tumors or embo-
lisms, which is thought to be a novel vehicle in medical
engineering [33]. However, whether exosomes could ac-
cess to podocytes or endothelial cells need to be further
studied to demonstrate a USCs exosomes - podocyte
interaction in vivo.
Exosomes have been studied in many acute kidney in-
jury (AKI) models such as ischemia–reperfusion injury
(IRI) [34], AKI [35], cisplatin-treated model [36], and so
forth. Previous studies indicated that, in a lethal mouse
AKI model, multiple injections of exosomes could de-
crease the mortality of AKI mice. The mechanism of
protection was mainly ascribed to an antiapoptotic effect
of exosomes [37, 38]. In vitro, studies demonstrated that
exosomes upregulated cisplatin-treated human tubular
epithelial cell antiapoptotic genes, such as Bcl-xl, Bcl2
and BIRC8, and downregulated genes that have a central
role in the execution-phase of cell apoptosis such as
Casp1, Casp8 and LTA [21]. Cantaluppi et al. previously
found that in an IRI model that microvesicles released
from progenitor cells activated an angiogenic program in
Fig. 7 ELISA assay of USC-CM and USCs-Exo for potential factors. The concentrations of VEGF, TGF-β, angiogenin and BMP-7 in control, USC-CM
and USCs-Exo were measured by ELISA. *P < 0.05, USC-CM versus control; #P < 0.05, USCs-Exo versus control. BMP-7 Bone morphogenetic protein-7,
TGF-β1 Transforming growth factor-β1, USC Urine-derived stem cell, VEGF Vascular endothelial growth factor
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endothelial cells by horizontal mRNA transfer. The RNA
content of microvesicles was enriched in microRNAs
that modulate proliferation, angiogenesis, and apoptosis
[39]. Recently, many studies had confirmed that exo-
somes could promote angiogenesis and inhibit apoptosis
[40–42]. We have investigated whether USCs-Exo pro-
mote endothelial cell proliferation by immunofluores-
cence of CD31 and Ki-67. The results showed some
endothelial areas with CD31- and Ki-67-positive cells
and confirmed glomerular angiogenesis. Based on previ-
ous studies, we proposed that exosomes derived from
USCs may have the ability to prevent kidney impairment
in diabetes. Our study indicated that injection of USCs-
Exo could reduce podocytic apoptosis by suppressing
overexpression of caspase-3 and promoting vascular re-
generation and cell survival, which may be related with
the potential cytokines VEGF, TGF-β1, angiogenin and
BMP-7 contained in USCs-Exo. Podocyte apoptosis was
inhibited, associated with BMP-7. Glomerular endothe-
lial cell proliferation and glomerular angiogenesis was
increased in diabetic rats due to VEGF, TGF-β and
angiogenin [13, 43, 44]. The expression of cytokines
such as VEGF or BMP-7 is important for podocyte and
endothelial cell survival. However, further studies, espe-
cially with regard to the mechanisms and pathways of
exosome actions on podocytes or endothelial cells, are
to be conducted.
Exosomes have been studied less in chronic damage
models; however, microvesicles or the exosomes could
also protect against the progression of chronic kidney
damage by inhibiting capillary rarefaction, glomerulo-
sclerosis, and tubulointerstitial fibrosis. It has been stud-
ied in a 6-month after IRI kidney model that rarefaction
of renal microvascular density in the presence of sustained
hypoxia is associated with an accelerated progression to-
ward chronic kidney disease. The microvesicles could sig-
nificantly reduce glomerulosclerosis, tubulointerstitial
fibrosis, and microvascular rarefaction, thus preserving
renal function [45]. Our study first indicated that exo-
somes could prevent kidney impairment at the early stage
in a diabetic model. The capacity of exosomes has made it
increasingly attractive as a potential treatment of DN.
Compared with other stem cells, USCs have their own
advantages, especially in urinary regenerative engineer-
ing. USCs have stem cell characteristics with a highly
proliferative capacity because of their expression of tel-
omerase activity. USCs have more homology with the
urinary system, though the origin of USCs is still a mat-
ter of debate. They can give rise to additional specialized
cell types, including osteocytes, chondrocytes, myocytes
and adipocytes. They can be easily and consistently
obtained by a noninvasive approach and extensively ex-
panded in vitro so that it is so easy to obtain sufficient
cells for use [46, 47]. Combining the advantages of USCs
and exosomes, USC-Exo will be a promising therapeutic
approach in regenerative medicine, with less immune re-
jection, better differentiation and a more stable and ad-
equate supply.
Conclusions
In conclusion, exosomes extracted from human urine-
derived stem cells could ameliorate kidney impairment
in type I diabetic rats. Exosomes may exhibit their effect
by inhibiting podocyte apoptosis or promoting angiogen-
esis and cell survival through potential factors. Overall,
the application of USCs-Exo may be a novel therapeutic
approach in the treatment of DN.
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